UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 1-U
Current Report Pursuant to Regulation A
Date of Report: February 3, 2020
(Date of earliest event reported)
Commission File No. 024-10924
CANNABINOID BIOSCIENCES, INC. |
California
(State or other jurisdiction of incorporation or organization)
Cannabinoid Biosciences, Inc.
370 Amapola Ave., Suite 200A
Torrance, California 90501
(323) 868-6762; (310) 895-1839
franklin@cbdxfund.com
(Address, including zip code, and telephone number,
including area code, of issuer’s principal executive office)
Patience C Ogbozor
370 Amapola Ave., Suite 200A
Torrance, California 90501
Telephone: (310) 895-1839
cannabinoidbiosciences@gmail.com
(Name, address, including zip code, and telephone number,
including area code, of agent for service)
Copy to:
Azuka L Uzoh, Esq.
Law Office of Azuka L Uzoh
1930 Wilshire Blvd., Suite 1216
Los Angeles, California 90025
Telephone: (213) 483-4020
2834 | 47-1077576 |
(Primary Standard Industrial | (IRS Employer |
Classification Code Number) | Identification Number) |
Item 4.01. Changes in Registrant’s Certifying Accountant.
On February 3, 2020, the Board of Directors (the “Board”) of Cannabinoid Biosciences, Inc. (the “Company”) approved the engagement of DylanFloyd Accounting & Consulting (“DylanFloyd”) as the Company’s new independent registered public accounting firm for the year ending December 31, 2019 and other reviews related to the Company’s plan to file Form S-1 later this quarter. The change became effective upon DylanFloyd’s completion of its standard client acceptance process and execution of attached engagement letter.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
| Description |
99.1 |
| Letter of DylanFloyd Accounting & Consulting dated February 3, 2020 |
SIGNATURES
Pursuant to the requirements of Regulation A, the issuer has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized in the Los Angeles, State of California, on February 7, 2020
Cannabinoid Biosciences, Inc.
By: | /s/ Frank I Igwealor |
Name: Frank I Igwealor, CPA, CMA, JD, MBA | |
Title: Sr. Vice President and Chief Financial Officer | |
